Clinical Trial: Role Of Phosphorus And FGF 23 In Patients With Dent Disease

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Role Of Phosphorus And FGF 23 In Patients With Dent Disease

Brief Summary: Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Detailed Summary:
Sponsor: Mayo Clinic

Current Primary Outcome: Change in 24 hr urine and serum after 2 weeks of phosphorus supplementation [ Time Frame: 6 months ]

This study will measure the changes in a 24 hr urine supersaturation and serum after phosphorus is taken for two weeks to decrease stone formation


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Mayo Clinic

Dates:
Date Received: December 6, 2013
Date Started: September 2014
Date Completion: June 2017
Last Updated: September 19, 2016
Last Verified: September 2016